# A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Source: https://onco.cc/trials/nct06054555/  
OnCo record `nct06054555` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab in melanoma, run by Amgen, active and no longer recruiting.

## Summary

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma is a phase 3 interventional study registered as NCT06054555 by Amgen, with 633 participants enrolled, started 2023-11-02 and due to reach its primary completion in 2028-01-25. Interventions recorded: ABP 206, Nivolumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06054555
- Phase: 3
- Setting: A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma
- Sponsor: Amgen
- Enrolled: 633

## Sources

- ClinicalTrials.gov NCT06054555: https://clinicaltrials.gov/study/NCT06054555

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06054555.json